{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-058036","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.153756+00:00","generated_at":"2026-06-02T17:10:18.987292+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Protagonist Q1 net income $207.3M on $255M Takeda revenue; cash runway through Q4 2027","bullets":["Net income of $207.3M ($3.26 diluted EPS) vs net loss of $33.7M in Q1 2023; revenue $255M from Takeda rusfertide license.","Cash, equivalents & marketable securities $322.6M at March 31, 2024; extended runway through Q4 2027 including $300M upfront from Takeda.","Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in psoriasis completed enrollment; Phase 3 ICONIC ADVANCE studies ongoing.","Expect to nominate oral IL-17 antagonist development candidate by end of 2024.","Rusfertide VERIFY study top-line data expected by Q1 2025; potential deal value with Takeda up to $630M plus profit share/royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-058036","json":"https://secwatch.observer/filing/0001104659-24-058036.json","markdown":"https://secwatch.observer/filing/0001104659-24-058036.md","text":"https://secwatch.observer/filing/0001104659-24-058036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924058036/0001104659-24-058036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924058036/tm2413671d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:10:18.987292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27b0f7df56e9e133dd64025deb6417dc38e8fc42","claim":"Protagonist Therapeutics, Inc reported first quarter ended March 31, 2024 results: revenue $255.0 million, net income $207,340 thousand, EPS $3.26 per diluted share.","evidence_excerpt":") Basic earnings (loss) per share $ 3.41 $ (0.67 ) Diluted earnings (loss) per share $ 3.26 $ (0.67 ) · License and Collaboration Revenue : License and collaboration revenue of $255.0 million for March 31, 2024 consisted of: (i) $254.1 million of the $300.0 million transaction price for the Takeda Collaboration Agreement allocated to the rusfertide license delivered","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924058036/0001104659-24-058036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$255.0 million"},{"label":"Net income","value":"$207,340 thousand"},{"label":"EPS","value":"$3.26 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}